You are here

  • Home
  • Archive
  • Volume 80, Issue 7
  • JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Article info

Article menu
Rheumatoid arthritis
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Authors

  1. Correspondence to Dr Julie A Di Paolo; julie.dipaolo{at}gilead.com
View Full Text

Citation

Traves PG, Murray B, Campigotto F, et al
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Annals of the Rheumatic Diseases 2021;80:865-875.

Publication history

  • Received September 1, 2020
  • Revised January 12, 2021
  • Accepted January 13, 2021
  • First published March 19, 2021.
Online issue publication 
July 06, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.